ReviewCancer metastasis reviews2016
One microenvironment does not fit all: heterogeneity beyond cancer cells.
Review in Cancer metastasis reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration.Cancer research · 2026Article
- Label-Free Monitoring of Cancer-Associated Fibroblast Activation Using NAD(P)H Fluorescence Lifetime Imaging.Chembiochem : a European journal of chemical biology · 2026Article
- Macroscopic polarimetric discrimination and quantification of antiangiogenic effect of AGRO aptamer and GK1 peptide in a preclinical melanoma model.Scientific reports · 2026Article
- Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy.Biomolecules · 2026Review
- An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset.Molecular cancer · 2026Article
- The Role of Kinase Inhibitors in Cancer Neuroscience: Mechanisms, Therapeutic Potential, and Future Directions.Anti-cancer agents in medicinal chemistry · 2026Review
- Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy.Frontiers in immunology · 2026Article
- Monocyte-to-lymphocyte ratio as a subtype-specific biomarker in breast cancer prognosis: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Distinctive GABA A receptor subunit expression modulates cell specific EMT and functional responses in glioblastoma breast and ovarian cancer.Scientific reports · 2025Article
- New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.Research (Washington, D.C.) · 2025Review
- Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment.Recent patents on anti-cancer drug discovery · 2025Article
- Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.Journal of cancer research and clinical oncology · 2024Article
- Assessing transcriptomic heterogeneity of single-cell RNASeq data by bulk-level gene expression data.BMC bioinformatics · 2024Article
- Clustering on hierarchical heterogeneous data with prior pairwise relationships.BMC bioinformatics · 2024Article
- The TGF-β Family in Glioblastoma.International journal of molecular sciences · 2024Review
- Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy.International journal of molecular sciences · 2023Article
- ERBB3 mediates the PI3K/AKT/mTOR pathway to alter the epithelial‑mesenchymal transition in cervical cancer and predict immunity filtration outcome.Experimental and therapeutic medicine · 2023Article
- The tumor-immune ecosystem in shaping metastasis.American journal of physiology. Cell physiology · 2023Review
- The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Frontiers in pharmacology · 2023Review
- A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Human cancers exhibit formidable molecular heterogeneity, to a large extent accounting for the incomplete and transitory efficacy of current anti-cancer therapies. However, neoplastic cells alone do not manifest the disease, but conscript a battery of non-tumor cells to enable and sustain hallmark capabilities of cancer. Escaping immunosurveillance is one of such capabilities. Tumors evolve immunosuppressive microenvironment to subvert anti-tumor immunity. In this review, we will focus on tumor-associated myeloid cells, which constitute an essential part of the immune microenvironment and reciprocally interact with cancer cells to establish malignancy toward metastasis. The diversity and plasticity of these cells constitute another layer of heterogeneity, beyond the heterogeneity of cancer cells themselves. We envision that immune microenvironment co-evolves with the genetic heterogeneity of tumor. Addressing the question of how genetically distinct tumors shape and are shaped by unique immune microenvironment will provide an attractive rationale to develop novel immunotherapeutic modalities. Here, we discuss the complex nature of tumor microenvironment, with an emphasis on the cellular and functional heterogeneity among tumor-associated myeloid cells as well as immune environment heterogeneity in the context of a full spectrum of human breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.